[Cause and prevention of nocturnal gastric acid breakthrough]

Nihon Rinsho. 2002 Feb:60 Suppl 2:779-83.
[Article in Japanese]
No abstract available

Publication types

  • Review

MeSH terms

  • 2-Pyridinylmethylsulfinylbenzimidazoles
  • Aryl Hydrocarbon Hydroxylases*
  • Benzimidazoles / pharmacology
  • Benzimidazoles / therapeutic use
  • Circadian Rhythm*
  • Cytochrome P-450 CYP2C19
  • Cytochrome P-450 Enzyme System / genetics
  • Esophagitis, Peptic / etiology
  • Gastric Acid / metabolism*
  • Helicobacter Infections / physiopathology
  • Helicobacter pylori
  • Histamine H2 Antagonists / pharmacology
  • Histamine H2 Antagonists / therapeutic use
  • Humans
  • Lansoprazole
  • Mixed Function Oxygenases / genetics
  • Omeprazole / analogs & derivatives*
  • Omeprazole / pharmacology
  • Omeprazole / therapeutic use
  • Polymorphism, Genetic
  • Proton Pump Inhibitors
  • Proton Pumps / physiology
  • Rabeprazole
  • Ranitidine / therapeutic use

Substances

  • 2-Pyridinylmethylsulfinylbenzimidazoles
  • Benzimidazoles
  • Histamine H2 Antagonists
  • Proton Pump Inhibitors
  • Proton Pumps
  • Lansoprazole
  • Rabeprazole
  • Ranitidine
  • Cytochrome P-450 Enzyme System
  • Mixed Function Oxygenases
  • Aryl Hydrocarbon Hydroxylases
  • CYP2C19 protein, human
  • Cytochrome P-450 CYP2C19
  • Omeprazole